公開日期 | 標題 | 作者 | 來源出版物 | WOS | 全文 |
2015 | A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia | Strati, P.; Tong, W. G.; Vitale, C.; Wierda, W. G.; O'Brien, S.; Brown, J. R.; Wen-Kai Weng ; Kipps, T.; Keating, M. J.; Ferrajoli, A. | Leukemia & Lymphoma | | |
2005 | A polymorphism in the C1qA component of complement correlates with prolonged complete remission following rituximab therapy of follicular lymphoma | Racila, E.; Wen-Kai Weng ; Wooldridge, J. E.; Link, B. K.; Levy, R.; Weiner, G. J. | Blood | | |
2008 | A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma | Racila, E.; Link, B. K.; Wen-Kai Weng ; Witzig, T. E.; Ansell, S.; Maurer, M. J.; Huang, J.; Dahle, C.; Halwani, A.; Levy, R.; Weiner, G. J. | Clinical Cancer Research | | |
2018 | Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sezary Syndrome | Dai, J.; Almazan, T. H.; Hong, E. K.; Khodadoust, M. S.; Arai, S.; Wen-Kai Weng ; Kim, Y. H. | Jama Dermatology | | |
2007 | The prediction of the dynamic and structural motions of a floating-pier system in waves | Lee, H. H.; Chen, L. Y.; Wen-Kai Weng ; Shyue, S. W. | Ocean Engineering | | |
2012 | Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence | Arai, S.; Sahaf, B.; Narasimhan, B.; Chen, G. L.; Jones, C. D.; Lowsky, R.; Shizuru, J. A.; Johnston, L. J.; Laport, G. G.; Wen-Kai Weng ; Benjamin, J. E.; Schaenman, J.; Brown, J.; Ramirez, J.; Zehnder, J. L.; Negrin, R. S.; Miklos, D. B. | Blood | | |
2008 | Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd | Arai, S.; Sahaf, B.; Jones, C.; Zhender, J.; Lowsky, R.; Strober, S.; Shizuru, J.; Negrin, R.; Johnston, L.; Laport, G.; Schaenman, J.; Brown, J.; Wen-Kai Weng ; Letsinger, R.; Wong, R.; Lavori, P.; Miklos, D. | Blood | | |
2011 | A prospective trial of low-dose total skin electron beam therapy in mycosis fungoides and proposal of a new clinically meaningful endpoint | Bashey, S.; Harrison, C.; Navi, D.; Lingala, B.; Armstrong, R.; Wen-Kai Weng ; Sundram, U.; Kim, Y. H.; Hoppe, R. | Journal Der Deutschen Dermatologischen Gesellschaft | | |
2022 | Relative Energy Variation Characteristics Considering Interaction between Waves and Vegetation Structure | Shih, Ruey-Syan ; Li, Chi-Yu ; Weng, Wen-Kai ; Lin, Chih-Hung | WATER-SUI | 0 | |
2012 | RETRACTED: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retracted article. See vol. 129, pg. 2595, 2019) | Kohrt, H. E.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Scheeren, F.; Czerwinski, D.; Colevas, A. D.; Wen-Kai Weng ; Clarke, M. F.; Carlson, R. W.; Stockdale, F. E.; Mollick, J. A.; Chen, L. P.; Levy, R. | Journal of Clinical Investigation | | |
2014 | RETRACTED: Targeting CD137 enhances the efficacy of cetuximab (Retracted article. See vol. 129, pg. 2595, 2019) | Kohrt, H. E.; Colevas, A. D.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Lund, P.; Mueller, A.; Sagiv-Barfi, I.; Marabelle, A.; Lira, R.; Troutner, E.; Richards, L.; Rajapaska, A.; Hebb, J.; Chester, C.; Waller, E.; Ostashko, A.; Wen-Kai Weng ; Chen, L. P.; Czerwinski, D.; Fu, Y. X.; Sunwoo, J.; Levy, R. | Journal of Clinical Investigation | | |
2019 | RETRACTION: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retraction of Vol 122, Pg 1066, 2012) | Kohrt, H. E.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Scheeren, F.; Czerwinski, D.; Colevas, A. D.; Wen-Kai Weng ; Clarke, M. F.; Carlson, R. W.; Stockdale, F. E.; Mollick, J. A.; Chen, L. P.; Levy, R. | Journal of Clinical Investigation | | |
2019 | RETRACTION: Targeting CD137 enhances the efficacy of cetuximab (Retraction of Vol 124, Pg 2668, 2014) | Kohrt, H. E.; Colevas, A. D.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Lund, P.; Mueller, A.; Sagiv-Barfi, I.; Marabelle, A.; Lira, R.; Troutner, E.; Richards, L.; Rajapaska, A.; Hebb, J.; Chester, C.; Waller, E.; Ostashko, A.; Wen-Kai Weng ; Chen, L. P.; Czerwinski, D.; Fu, Y. X.; Sunwoo, J.; Levy, R. | Journal of Clinical Investigation | | |
2016 | Risk of Non-Melanoma Skin Cancer Following Hematopoietic Cell Transplantation and Voriconazole-Associated Risk | Kuklinski, L. F.; Li, S. F.; Karagas, M. R.; Kwong, B. Y.; Wen-Kai Weng | Blood | | |
2005 | Rituximab variants with re-engineered Fc with higher affinity to activating Fc gamma R eliminate the functional difference between Fc gamma R genotypes | Wen-Kai Weng ; Stavenhagen, J.; Koenig, S.; Levy, R. | Blood | | |
2001 | Rituximab-induced Annexin-V staining of tumor cells does not predict clinical outcome following Rituximab treatment in follicular non-Hodgkin's lymphoma | Wen-Kai Weng ; Levy, R. | Blood | | |
2002 | Rituximab-induced antibody-dependent cellular cytotoxicity (ADCC) in follicular non-Hodgkin's lymphoma | Wen-Kai Weng ; Levy, R. | Blood | | |
1995 | SIGNALING THROUGH CD19 ACTIVATES AP1 TRANSCRIPTION FACTORS IN HUMAN B-LINEAGE CELLS | Wen-Kai Weng ; Obrien, D.; Vanness, B.; Lebien, T. W. | Faseb Journal | | |
2016 | A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT) | Kim, Y. H.; Hoppe, R. T.; Rook, A. H.; Maity, A.; Geskin, L. J.; Horowitz, D. P.; Finnegan, G.; Khodadoust, M.; Wen-Kai Weng ; Lares, A.; Hong, E. K. J.; Buchanan, M.; Ma, V.; Kha, H.; Lawrence, C. E.; Vainstein, V.; Basile, L. A. | Blood | | |
2001 | Studies on modifications of ITO surfaces in OLED devices by Taguchi methods | Liu, J. M.; Lu, P. Y.; Wen-Kai Weng | Materials Science and Engineering B-Solid State Materials for Advanced Technology | | |